DATA SHEET PROGYNOVA - Medsafe
160419 PROGYNOVA DS 1 DATA SHEET . PROGYNOVA ® oestradiol valerate tablets . Presentation PROGYNOVA 1 mg: The memo-pack …
Download DATA SHEET PROGYNOVA - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Production Tongkat Ali Tablet BMR-001 0 - ASEAN
asean.orgCOMPANY NAME BATCH MANUFACTURING RECORD Page: 1 of 8 Department : Production Title : Tongkat Ali Tablet Batch Record : …
Tablet Coating Musts - Techceuticals
techceuticals.comW hen it comes to coating tablets there are musts that really count and then there are the other things. The ability to coat tablets well is often
coatings for tooling - TIN Coating, Titanium Nitride …
www.beamalloy.netorigt lising alts asls coatings for tooling If tabletting equipment is the engine driving your manufactur-ing operation, you want to keep it running as smoothly and
New Zealand Datasheet 1 PRODUCT NAME …
www.medsafe.govt.nzNew Zealand Datasheet 1 PRODUCT NAME BUCCALINE tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Haemophilus influenzae, pneumococci (I, II, III), streptococci, staphylococci.
Enteric coating of ibuprofen tablets (200 mg) using …
www.scielo.brEnteric coating of ibuprofen tablets (200 mg) using an aqueous dispersion system 101 logies, Inc. Wayne, NJ) and Magnesium Stearate (FMC Corporation, USA) were used as directly compressible
Tablets & Capsules September 2013 …
www.techceuticals.comTablet weight and the feeder assembly Weights can vary if the paddle feeder overworks the powder and changes its characteristics, Mossop said. His
REVISION OF MONOGRAPH ON TABLETS - World …
www.who.intDocument QAS/09.324/Final March 2011 REVISION OF MONOGRAPH ON TABLETS Final text for addition to The International Pharmacopoeia This monograph was adopted by the Forty-fourth WHO Expert Committee on